Urologic Diseases  >>  Thymoglobulin (anti-thymocyte globulin (rabbit))  >>  Phase 4
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
NCT01046955: Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

Completed
4
38
US
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab, Thymoglobulin, Zenapax
University of Miami, Hoffmann-La Roche
End-Stage Renal Disease, Living Donors
04/07
12/08
NCT00275535: The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Completed
4
165
US
Anti-thymocyte globulin, Thymoglobulin, Atgam, Mycophenolate mofetil, CellCept, Prednisone, Deltasone, Liquid Pred, Meticorten, Orasone, Prednicen-M, Prednicot, Sterapred, Sterapred DS, Tacrolimus, Prograf, Advagraf, Protopic, Sirolimus, Rapamune
Mayo Clinic, Wyeth is now a wholly owned subsidiary of Pfizer, Genzyme, a Sanofi Company, Roche Pharma AG
Kidney Diseases
11/07
12/08
NCT00374803: Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

Completed
4
45
US
Mycophenolic Acid (Myfortic), mycophenolic acid enteric coated
University of Cincinnati, Novartis
End Stage Renal Disease (ESRD)
01/08
01/08
NCT01172418: Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Completed
4
200
US
Alemtuzumab, Campath-1H (Alemtuzumab), Daclizumab, Zenapax (Daclizumab), Thymoglobulin, rATG (rabbit antithymocyte globulin)
University of Miami
Transplant; Failure, Kidney
05/10
05/10
NCT00556933: Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

Completed
4
180
US
rabbit anti-thymocyte globulin - single dose, Thymoglobulin, rATG, mycophenolate mofetil, CellCept, MMF, mycophenolic acid, Myfortic, rabbit anti-thymocyte globulin - 4 doses, sirolimus, Rapamune, rapamycin, tacrolimus, FK506, ProGraf
University of Nebraska, Genzyme, a Sanofi Company
End-stage Renal Disease
04/11
06/11
NCT01312064: De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Terminated
4
2
RoW
rituximab and everolimus, mabthera, thymoglobulin and tacrolimus, ATG
National Taiwan University Hospital
Renal Insufficiency
04/12
04/12
BelatPilot, NCT02130817: Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Withdrawn
4
0
US
Belatacept, Nujolix, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Anti-thymocyte globulin, Myfortic, Steroids, Dexamethasone, Prednisone
University of Wisconsin, Madison, Bristol-Myers Squibb
End Stage Renal Disease, Antibody Mediated Rejection
10/15
10/15
TRANSFORM , NCT01950819 / 2013-000322-66: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Completed
4
2037
Japan, US, Europe, RoW
Induction therapy, Simulect, basiliximab, rATG, Thymoglobulin, Corticosteroids, prednisone, methylprednisone, methylprednisolone, etc., EVR+rCNI, Zortress, Certican, Neoral, Prograf, MPA+sCNI, Myfortic, Cellcept, Neoral, Prograf
Novartis Pharmaceuticals
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
02/17
01/18

Download Options